These findings are timely, with recent clinical observations (8, 10, 12) showing how within the HR+ BC subtype, ERα expression is associated with a reduced immune-reactive signature (10), immune infiltration (20, 21, 23), and responses to ICB therapies. Here, ESR1 is linked to breast cancer.